81 related articles for article (PubMed ID: 8838560)
1. [Gene therapy in neurology. State of the art and future prospects].
Duarte RG
Neurologia; 1995 Dec; 10 Suppl 1():56-61. PubMed ID: 8838560
[TBL] [Abstract][Full Text] [Related]
2. [Advance of gene therapy for neurological diseases by direct in vivo gene transfer].
Li BY; Liu C; Wang HX
Sheng Li Ke Xue Jin Zhan; 1996 Jul; 27(3):215-20. PubMed ID: 9772359
[TBL] [Abstract][Full Text] [Related]
3. Intraarterial delivery of genetic vectors for the treatment of malignant brain tumors.
Cohen ZR; Duvdevani R; Nass D; Hadani M; Ram Z
Isr Med Assoc J; 2001 Feb; 3(2):117-20. PubMed ID: 11344821
[TBL] [Abstract][Full Text] [Related]
4. A defective herpes simplex virus vector system for gene delivery into the brain: comparison with alternative gene delivery systems and usefulness for gene therapy.
Neve RL; Geller AI
Clin Neurosci; 1995-1996; 3(5):262-7. PubMed ID: 8914792
[TBL] [Abstract][Full Text] [Related]
5. Nervous system modification by transplants and gene transfer.
Doering LC
Bioessays; 1994 Nov; 16(11):825-31. PubMed ID: 7840760
[TBL] [Abstract][Full Text] [Related]
6. Viral gene therapy strategies: from basic science to clinical application.
Young LS; Searle PF; Onion D; Mautner V
J Pathol; 2006 Jan; 208(2):299-318. PubMed ID: 16362990
[TBL] [Abstract][Full Text] [Related]
7. Eradication of murine brain tumors by direct inoculation of concentrated high titer-recombinant retrovirus harboring the herpes simplex virus thymidine kinase gene.
Tamura K; Tamura M; Ikenaka K; Yoshimatsu T; Miyao Y; Nanmoku K; Shimizu K
Gene Ther; 2001 Feb; 8(3):215-22. PubMed ID: 11313793
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses.
Alemany R; Gomez-Manzano C; Balagué C; Yung WK; Curiel DT; Kyritsis AP; Fueyo J
Exp Cell Res; 1999 Oct; 252(1):1-12. PubMed ID: 10502394
[TBL] [Abstract][Full Text] [Related]
9. [Gene therapy for brain tumors--present conditions and prospects].
Nakahara N; Yoshida J
Gan To Kagaku Ryoho; 2005 Apr; 32(4):458-62. PubMed ID: 15853210
[TBL] [Abstract][Full Text] [Related]
10. Efficient gene delivery into epstein-barr virus (EBV)-transformed human B cells mediated by replication-defective herpes simplex virus-1 (HSV-1): A gene therapy model for EBV-related B cell malignancy.
Suzuki T; Piche A; Kasono K; Xiang J; Gomez-Navarro J; Moriuchi S; Krisky DM; Oligino T; Glorioso JC; Curiel TJ; Curiel DT
Biochem Biophys Res Commun; 1998 Nov; 252(3):686-90. PubMed ID: 9837767
[TBL] [Abstract][Full Text] [Related]
11. Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle.
Akkaraju GR; Huard J; Hoffman EP; Goins WF; Pruchnic R; Watkins SC; Cohen JB; Glorioso JC
J Gene Med; 1999; 1(4):280-9. PubMed ID: 10738561
[TBL] [Abstract][Full Text] [Related]
12. An experimental application of gene therapy for human retinoblastoma.
Hayashi N; Ido E; Ohtsuki Y; Ueno H
Invest Ophthalmol Vis Sci; 1999 Feb; 40(2):265-72. PubMed ID: 9950583
[TBL] [Abstract][Full Text] [Related]
13. Total vascular exclusion of the liver enhances the efficacy of retroviral-mediated associated thymidine kinase and interleukin-2 genes transfer against multiple hepatic tumors in rats.
Alves A; Charre L; Panis Y; Cardoso J; Fabre M; Brisson E; Houssin D; Soubrane O; Klatzmann D
Surgery; 2003 Jun; 133(6):669-77. PubMed ID: 12796736
[TBL] [Abstract][Full Text] [Related]
14. [Gene therapy for brain tumors: experimental treatment of malignant brain tumors using recombinant herpes simplex virus type 1 (series 7)].
Mineta T; Tabuchi K; Martuza RL
No Shinkei Geka; 1995 Apr; 23(4):285-92. PubMed ID: 7739766
[No Abstract] [Full Text] [Related]
15. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.
Sinn PL; Sauter SL; McCray PB
Gene Ther; 2005 Jul; 12(14):1089-98. PubMed ID: 16003340
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy in the CNS.
Costantini LC; Bakowska JC; Breakefield XO; Isacson O
Gene Ther; 2000 Jan; 7(2):93-109. PubMed ID: 10673714
[TBL] [Abstract][Full Text] [Related]
17. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
18. Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: consequences for anti-cancer gene therapy.
Hoshi M; Harada A; Kawase T; Uyemura K; Yazaki T
Cancer Gene Ther; 2000 May; 7(5):799-805. PubMed ID: 10830727
[TBL] [Abstract][Full Text] [Related]
19. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
20. Coexpression of a multidrug resistance gene (MDR1) and herpes simplex virus thymidine kinase gene in a bicistronic retroviral vector Ha-MDR-IRES-TK allows selective killing of MDR1-transduced human tumors transplanted in nude mice.
Sugimoto Y; Sato S; Tsukahara S; Suzuki M; Okochi E; Gottesman MM; Pastan I; Tsuruo T
Cancer Gene Ther; 1997; 4(1):51-8. PubMed ID: 9012451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
